Adverse reactions to liver drug lamivudine and telbivudine

Business News Agency July 27th The National Drug Adverse Reactions Monitoring Center recently released the 30th Drug Adverse Drug Reaction Information Bulletin, saying that hepatitis drugs Lamivudine and telbivudine can cause severe adverse reactions to rhabdomyolysis. The State Food and Drug Administration once again reminded medical workers, drug manufacturers and the public to be alert to the risk of riamvudine and telbivudine causing rhabdomyolysis.

The State Food and Drug Administration suggested that clinicians should fully consider the patient's condition and the possible risks in medication when choosing drugs, and inform the patients about possible drug risks. The patients should be monitored for creatine phosphokinase during the course of continuous drug use. Changes, as well as liver, kidney function tests and other indicators. In the event of severe rhabdomyolysis, metabolic disorders and acute renal failure that may jeopardize the life of the patient may occur, and active treatment measures should be taken immediately.

The State Food and Drug Administration requires manufacturers to strengthen post-marketing safety studies and follow-up monitoring of adverse reactions, and ensure that product risk information can be communicated to medical personnel and patients in a timely manner. Drug manufacturers also need to take effective measures to minimize serious drugs. Repeated adverse reactions occurred to protect the public's drug safety.